CD19 binding molecules and uses thereof

US12221481B2 · kind B2 · utility

Assignee

• Novartis AG · CH

Inventors

• Brian Granda · Cambridge, US
• Amy Rayo · Cambridge, US
• Connie Hong · Somerville, US
• Dattananda Chelur · Cambridge, US
• Haihui Lu · Cambridge, US
• Regis Cebe · Saint-Louis, FR
• Sunyoung Jang · Cambridge, US

Key dates

• Filing date: May 19, 2020
• Grant date: Feb 11, 2025
• Expiry date: May 4, 2042

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/31
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present disclosure provides CD19 binding molecules that specifically bind to CD19, including monospecific, bispecific and trispecific binding molecules, conjugates comprising the CD19 binding molecules, and pharmaceutical compositions comprising the CD19 binding molecules and the conjugates. The disclosure further provides methods of using the C19 binding molecules to treat diseases and disorders associated with expression of CD19. The disclosure yet further provides recombinant host cells engineered to express the CD19 binding molecules and methods of producing the CD19 binding molecules by culturing the host cells under conditions in which the CD19 binding molecules are expressed.